PFE (Pfizer) How high will it go? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go?

PFE 25.16

-0.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BiGx who wrote (6160)	10/26/1998 1:03:00 PM
From: Anthony Wong	Read Replies (1) of 9523

BiGx, CNBC reported just now that PFE and Neurogen (NRGN) is developing a sleeping pill that reportedly has very few side effects. This may be one of the reasons for PFE's strength today. The following is a Sept. press release which gives more information on the drug: news.com INSOMNIA PROGRAM -- NGD 96-1 The NGD 96-1 IND was filed by Pfizer Inc., with whom Neurogen is collaborating to develop drugs to treat sleep disorders, anxiety, dementia and obesity. Pfizer plans to begin clinical studies this fall and will conduct all human clinical trials of Neurogen's sedative/hypnotic compounds from the collaboration. The initial double-blind Phase I human clinical trial of NGD 96-1 will evaluate the pharmacokinetics and safety of single doses of the compound or a placebo administered to several dosing groups of normal healthy volunteers. Pre-clinical studies of NGD 96-1, discovered by Neurogen, demonstrate that the drug candidate enhances sleep onset while significantly reducing many of the side effects associated with current sedative/hypnotic therapies such as cognitive impairment, tolerance, physical dependence, hangover effects and interaction with alcohol. Worldwide sales of currently marketed prescription drugs to treat insomnia totaled $1.7 billion in 1997, according to IMS data. "The synergism between Neurogen and Pfizer creates a powerful combination. Pfizer's ability to develop and market new drugs is complemented by Neurogen's proven expertise in discovering receptor subtype specific drug candidates," said Harry H. Penner, President and CEO of Neurogen. "Neurogen's insomnia program is the third drug development program to begin human clinical trials from our four collaborative programs with Pfizer."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next